General Market Opportunity for FluoroPharma Medical, Inc. (FPMI)
FluoroPharma Medical is a developer of unique, targeted molecular imaging pharmaceuticals used with positron emission tomography (PET). Although the company is focused primarily on the detection of cardiovascular disease (CAD) related processes, the company has other imaging agents in the pipeline. The company’s market opportunity is based largely upon their lead products: • CardioPET detects regions of metabolic insufficiency, for cardiac viability assessment. • BFPET measures cardiovascular blood flow, and is designed for myocardial perfusion imaging. • VasoPET detects vulnerable coronary artery plaque, an especially dangerous form of plaque. The size of the FluoroPharma market can be viewed as directly…